Opening a new chapter in regenerative medicine and expanding into the global market; Emerging Stock Board registration expected in 2025

The first medical seminar hosted by StellarCell.Bio came to a successful conclusion on August 18. Dr. Fang, Peng Xiang , Director of the Department of Neurosurgery at Yuankuo Hospital, was invited to share his extensive experience in the field of neurospinal treatment. Director Fang leverages advanced instruments and technologies to provide precise and timely treatments, accelerating patient recovery. During the seminar, he provided an in-depth exploration of the latest advancements in neurosurgery, with a particular focus on therapeutic applications, offering participating physicians fresh and comprehensive insights and inspiring enthusiasm for future innovations in treatment.
The event was organized by Lin, Xin Yi, CEO of Starnic Group, who brought together top physicians on the Starnic Preventive Medicine platform. Attendees made a visit to DrSignal Biotechnology’s fully automated GTP-compliant laboratory at the National Biotechnology Research Park in Nangang, followed by a series of sessions at the Courtyard by Marriott Taipei, marking a new milestone in the development of regenerative medicine.
In addition, nearly 30 distinguished guests of Star Clinic participated in conferences, jointly exploring the future of regenerative medicine. The development and clinical application of wound care therapeutics demonstrated remarkable potential in the fields of scientific research and aesthetic medicine. Dr. Chen, Yi Ting , Deputy Director of Star Clinic, shared new technologies and applications designed to assist patients in achieving faster post-procedure recovery, which further enhanced attendees' confidence in aesthetic and preventive medicine and contributed significantly to the event's success.
Founded in 2023, StellarCell.Bio specializes in the development of new wound care therapeutics. Through collaborations with major preventive medicine and aesthetic medicine clinics, as well as relevant medical departments in Taiwan, we are building the largest intellectual property database of clinical data for wound care treatment in Taiwan. Our vision is to expand globally to become a leading innovator in the development of post-procedure wound care therapeutics. Plans are underway to launch an IPO and be listed on the Emerging Stock Board in 2025, using Taiwan’s world-class medical technology to elevate global health.
StellarCell.Bio will continue to forge new frontiers in Taiwan’s regenerative medicine sector with steadfast commitment in the future. We are dedicated to tightly integrating cutting-edge biotechnology R&D with clinical practice, writing a new chapter for preventive medicine in Taiwan and illuminating a beacon of hope for human health and well-being.